VCNX

Vaccinex, Inc. (VCNX) | Rumor.io

Vaccinex

VCNX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.1

Market capitalization3.1M

Earnings per share-8.88

Dividend yield (TTM)—

Revenue (annual)601K

Net income (annual)-18.6M

Social

What share of all stock conversation is about VCNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 23

Vaccinex, Inc. (VCNX) announced a $60 million agreement to finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease.
The trial aims to determine the effectiveness and safety of the drug, and if successful, could move on to Phase 3.
The funding has led to a surge in VCNX shares, with some investors expressing both bullish and bearish sentiments on the deal.

Generated by AI

Sentiment

Of the messages about VCNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	45.35% -29.42
Bearish	—	—	—	54.65% +29.42

Bullish· Dec 17

$VCNX has a strong pipeline and the product is ready, suggesting a positive outlook for the company.
The insider buying activity is seen as legitimate, with the company's founders possibly preparing to benefit from the delisting to OTC market.
The delisting to OTC market may be a precursor to a buyout, providing a potential upside for investors who hold strong.

Bearish· Dec 17

The company's delisting from a major exchange may have been orchestrated by big investors to facilitate a sell-off by small shareholders.
The insider ownership and lack of transparency surrounding the company's partnerships with major pharmaceutical companies raises questions about the company's intentions and potential corruption.
The company's recent actions, including delisting and potential plans to go private, may be aimed at exploiting retail investors and maximizing profits for insiders.

Generated by AI

Topics

Of the messages about VCNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	82.43%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	1.35%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	16.22%

Announcements· Oct 6

$VCNX CEO bought 3 million shares, with insiders loading up on the stock and a PR announcing a closed offering expected.
Vaccinex Insider Bought Shares Worth $3,000,000, according to a Recent SEC Filing, with the CEO buying 510k shares for $509.5k.
$VCNX stock is up 26% today on insider buying, with a tiny float and insiders expecting the stock to be up over $3.00.

Technical Analysis· Oct 6

$VCNX is seen as a potential trade setup with a scale-out area between.86 and.96.
A 20%+ move from the.80s analysis is expected, with a next resistance break coming up, and a potential short against the 1.25-1.30 range.
Closing above $1.16 resistance could bring strong after-hours trading movement, with a test of $2.00 and a possible double bottom formation.

Generated by AI

Community

Of the messages about VCNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	88.64%
Newcomers	—	—	—	11.36%

Regulars· Oct 6

The stock has shown a significant 30% move from the .80s analysis, and there's a possibility of a short squeeze leading to a further price increase.
The stock has already seen a 20%+ increase from the same analysis, and another resistance break is expected, with the next target at $0.16.
The stock is up 26% due to insider buying, and there's a possibility of a multi-day runner, with a low float of 2m shares and a high volume of 129X.

Newcomers· Oct 6

Newcomers are focused on insider buying activity, highlighting the stock's low market capitalization and the significant amount of shares purchased by insiders at a low price.
The discussion is centered on separating fact from noise, with a focus on the stock's analyst price target, the company's plans to close a deal, and the potential for a short thesis.
New investors are observing the stock's price action, specifically the break above $1.24 and the potential for a reversal, with some comparing the stock's price movement to a previous successful trade.

Generated by AI

Also Discussed

Investors talking about VCNX also mention

#	Name	Attention
1	Socket Mobile Inc.SCKT	0%0
2	ReTo Eco-Solutions Inc. Class A SharesRETO	0.01%0
3	CLPS Inc.CLPS	0%new
4	RCM Technologies Inc.RCMT	0%new
5	Applied UV, Inc.AUVI	0%0
6	Artelo Biosciences, Inc.ARTL	0%0
7	Cetus Capital Acquisition Corp. - Class A Common StockCETU	0%0
8	TDH Holdings, Inc.PETZ	0%new
9	Meiwu Technology Co., Ltd. Ordinary SharesWNW	0%0
10	ENTO - Entero Therapeutics, Inc.	——

Vaccinex, Inc.

Healthcare
Biotechnology

Vaccinex, Inc. is a clinical-stage biotechnology company focused on the discovery and development of targeted biotherapeutics for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. The company’s primary innovation centers on its lead drug candidate, pepinemab, a humanized monoclonal antibody designed to block semaphorin 4D (SEMA4D), a signaling molecule implicated in driving neuroinflammation and tumor immune evasion. Pepinemab is under clinical investigation for several challenging conditions, including Huntington’s disease and Alzheimer’s disease, where it aims to attenuate disease progression by reducing neuroinflammation, as well as for various cancers where it is evaluated in combination with checkpoint inhibitors to potentially enhance anti-tumor immunity. Beyond its therapeutic portfolio, Vaccinex leverages its proprietary ActivMAb® drug discovery platform to enable efficient antibody selection against complex membrane targets, supporting future pipeline expansion and broader collaborations across the biopharmaceutical industry. With headquarters in Rochester, New York, Vaccinex plays a specialized role in advancing innovative treatments for diseases with significant unmet medical needs, impacting both the oncology and neurology sectors.

Website

Location

1895 Mount Hope Avenue

Rochester, NY, 14620

United States

Social

What share of all stock conversation is about VCNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 23

Vaccinex, Inc. (VCNX) announced a $60 million agreement to finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease.
The trial aims to determine the effectiveness and safety of the drug, and if successful, could move on to Phase 3.
The funding has led to a surge in VCNX shares, with some investors expressing both bullish and bearish sentiments on the deal.

Generated by AI

Sentiment

Of the messages about VCNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	45.35% -29.42
Bearish	—	—	—	54.65% +29.42

Bullish· Dec 17

$VCNX has a strong pipeline and the product is ready, suggesting a positive outlook for the company.
The insider buying activity is seen as legitimate, with the company's founders possibly preparing to benefit from the delisting to OTC market.
The delisting to OTC market may be a precursor to a buyout, providing a potential upside for investors who hold strong.

Bearish· Dec 17

The company's delisting from a major exchange may have been orchestrated by big investors to facilitate a sell-off by small shareholders.
The insider ownership and lack of transparency surrounding the company's partnerships with major pharmaceutical companies raises questions about the company's intentions and potential corruption.
The company's recent actions, including delisting and potential plans to go private, may be aimed at exploiting retail investors and maximizing profits for insiders.

Generated by AI

Topics

Of the messages about VCNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	82.43%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	1.35%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	16.22%

Announcements· Oct 6

$VCNX CEO bought 3 million shares, with insiders loading up on the stock and a PR announcing a closed offering expected.
Vaccinex Insider Bought Shares Worth $3,000,000, according to a Recent SEC Filing, with the CEO buying 510k shares for $509.5k.
$VCNX stock is up 26% today on insider buying, with a tiny float and insiders expecting the stock to be up over $3.00.

Technical Analysis· Oct 6

$VCNX is seen as a potential trade setup with a scale-out area between.86 and.96.
A 20%+ move from the.80s analysis is expected, with a next resistance break coming up, and a potential short against the 1.25-1.30 range.
Closing above $1.16 resistance could bring strong after-hours trading movement, with a test of $2.00 and a possible double bottom formation.

Generated by AI

Community

Of the messages about VCNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	88.64%
Newcomers	—	—	—	11.36%

Regulars· Oct 6

The stock has shown a significant 30% move from the .80s analysis, and there's a possibility of a short squeeze leading to a further price increase.
The stock has already seen a 20%+ increase from the same analysis, and another resistance break is expected, with the next target at $0.16.
The stock is up 26% due to insider buying, and there's a possibility of a multi-day runner, with a low float of 2m shares and a high volume of 129X.

Newcomers· Oct 6

Newcomers are focused on insider buying activity, highlighting the stock's low market capitalization and the significant amount of shares purchased by insiders at a low price.
The discussion is centered on separating fact from noise, with a focus on the stock's analyst price target, the company's plans to close a deal, and the potential for a short thesis.
New investors are observing the stock's price action, specifically the break above $1.24 and the potential for a reversal, with some comparing the stock's price movement to a previous successful trade.

Generated by AI

Vaccinex

Social

Dec 23

Sentiment

Bullish· Dec 17

Bearish· Dec 17

Topics

Announcements· Oct 6

Technical Analysis· Oct 6

Community

Regulars· Oct 6

Newcomers· Oct 6

Also Discussed

Vaccinex, Inc.

Company Information

Location

Also Discussed

Social

Dec 23

Sentiment

Bullish· Dec 17

Bearish· Dec 17

Topics

Announcements· Oct 6

Technical Analysis· Oct 6

Community

Regulars· Oct 6

Newcomers· Oct 6